Fundraising Fox
/Companies
Sign in

AdvanCell Isotopes

Cambridge, US · Founded 2026 · Delaware corporation · 99 employees on LinkedIn · 9 known investors

Find your way into AdvanCell Isotopes

759 people in our graph share verified history with the AdvanCell Isotopes team — schools, employers, funds. One of them is your warm intro.

Graham Millsunlockedknows Aaron Pickett · together at AdvanCell (overlapped)
×3knows the team · via Freehills
×6knows the team · via Allen & Overy
×2knows the team · via University of Canterbury

AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung. Its lead-212-based programs, such as ADVC001 for metastatic prostate cancer, are in clinical development.

BiotechHealthtechMedical Devices

Founders & leadership

AdvanCell Isotopes was founded in 2026 by Andrew Adamovich.

AAAndrew Adamovich
Andrew AdamovichFounder & Managing Director, AustraliaAndrew Adamovich is Director at AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer treatment. He has prior experience in venture capital and private equity, with expertise in corporate development and mergers and acquisitions.
PLPhilina Lee
Philina LeeChief Executive OfficerExecutive Officer, Director at AdvanCell
APAaron Pickett
Aaron PickettHead of Legal & HR, Company SecretaryAaron Pickett is Executive Officer overseeing legal and HR functions at AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer treatment. He previously spent over nine years as General Counsel at GenesisCare and worked at law firms including Allen & Overy, Herbert Smith Freehills, and MinterEllisonRuddWatts, with expertise in mergers and acquisitions, capital offerings, and healthcare regulation.

Board

WC
Wing Cheong LamBoard director
NE
Nik EconomopoulosBoard director
AA
Anthony AiudiBoard director
BMBali Muralidhar
Bali MuralidharBoard directorGlobal Head of Life Sciences & CIO at Abingworth
JBJamil Beg
Jamil BegBoard of DirectorsPartner at 5AM Ventures
CGChristopher Gagliardi
Christopher GagliardiBoard MemberPrincipal at Sanofi Ventures
KC
Kevin CameronBoard director
AK
Andrew KayBoard director

Investors · 9

Catalio Capital Management, LPlisted by Catalio Capital Management, LPNew York

How we know: Catalio Capital Management, LP's portfolio page · Not right? Tell us

Proto Axiomlisted by Proto AxiomSydney

How we know: Proto Axiom's portfolio page · Not right? Tell us

Sanofi Ventureslisted by Sanofi VenturesCambridge · $5M

How we know: Sanofi Ventures's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us

SV Health Investorslisted by SV Health InvestorsLondon · $1M – $20M

How we know: SV Health Investors's portfolio page · a partner's Signal profile · Not right? Tell us

Tenmilelisted by Tenmile

How we know: Tenmile's portfolio page · Not right? Tell us

AbingworthreportedLondon · $15M – $30Mvia Bali Muralidhar · board

How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us

Ally Bridge GroupreportedNew York

How we know: press coverage · funding news · Not right? Tell us

T. Rowe PricereportedBaltimore

How we know: funding news · Not right? Tell us

Funding

SEC filings, press & company announcements

$533.3M disclosed across 2 rounds · 2026

▶$218.3MraisedJul 2026 · 41 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Philina LeeExecutive Officer, Director
  • Aaron PickettExecutive Officer
  • Wing Cheong LamDirector
  • Nik EconomopoulosDirector
  • Anthony AiudiDirector
  • Bali MuralidharDirector
  • Jamil BegDirector
  • Christopher GagliardiDirector
  • Andrew AdamovichDirector
  • Andrew KayDirector
  • Kevin CameronDirector
Offering amount
$315M
Amount sold
$218.3M
First sale
Jun 2026
Incorporated
Corporation, Delaware, 2026
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
AvenCell9 shared keywordsAvenCell Therapeutics develops next-generation cell therapies for hard-to-treat cancers, including solid tumors, combining switchable universal CAR-T technology with a CRISPR/Cas9-based allogeneic platform. The clinical-stage biopharmaceutical company creates autologous and allogeneic reprogrammable T-cell products and operates in both the US and Europe.
Applied StemCell6 shared keywordsApplied StemCell is a genome engineering platform company that develops proprietary technologies and iPSC expertise to enable safe, scalable integration of large DNA payloads into the mammalian genome for gene and cell-based medicine. The company provides end-to-end solutions for academia and biopharma partners to accelerate therapeutic development.

Companies competing with AdvanCell Isotopes for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

AdvanCell Closes US $315 Million Oversubscribed Series D Financing to Advance Targeted Alpha Therapies and Expand Clinical and Commercial Manufacturing Infrastructure - AdvanCelladvancell.com.au · Jul 2026

Frequently asked questions

What does AdvanCell Isotopes do?
AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung. Its lead-212-based programs, such as ADVC001 for metastatic prostate cancer, are in clinical development.
Who founded AdvanCell Isotopes?
AdvanCell Isotopes was founded by Andrew Adamovich in 2026.
Who are AdvanCell Isotopes's investors?
AdvanCell Isotopes's investors include Bain Capital Life Sciences, Catalio Capital Management, LP, Proto Axiom, Sanofi Ventures, SV Health Investors, Tenmile, Abingworth, Ally Bridge Group and 1 more.
How much funding has AdvanCell Isotopes raised?
AdvanCell Isotopes has disclosed $533.3M raised across 2 rounds.
Where is AdvanCell Isotopes headquartered?
AdvanCell Isotopes is headquartered in Cambridge, US.